Title |
Novel agents in the treatment of multiple myeloma: a review about the future
|
---|---|
Published in |
Journal of Hematology & Oncology, June 2016
|
DOI | 10.1186/s13045-016-0282-1 |
Pubmed ID | |
Authors |
Leonard Naymagon, Maher Abdul-Hay |
Abstract |
Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Egypt | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Unknown | 171 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 29 | 17% |
Student > Master | 22 | 13% |
Researcher | 21 | 12% |
Student > Ph. D. Student | 18 | 10% |
Other | 17 | 10% |
Other | 28 | 16% |
Unknown | 37 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 46 | 27% |
Biochemistry, Genetics and Molecular Biology | 30 | 17% |
Agricultural and Biological Sciences | 17 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 12 | 7% |
Immunology and Microbiology | 7 | 4% |
Other | 22 | 13% |
Unknown | 38 | 22% |